Trevi Therapeutics (TRVI) Preferred Stock Liabilities (2018 - 2019)

Trevi Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $21.2 million for Q1 2019.

• In Q1 2019, Preferred Stock Liabilities changed N/A year-over-year to $21.2 million; the TTM figure through Mar 2019 stood at $21.2 million (changed N/A YoY), while the FY2018 annual figure was $33.7 million, changed N/A from the prior year.
• Preferred Stock Liabilities for Q1 2019 stood at $21.2 million, down from $33.7 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $33.7 million in Q4 2018, with the low at $21.2 million in Q1 2019.